4//SEC Filing
CANAAN X L.P. 4
Accession 0001123292-19-000749
CIK 0001661059other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 7:32 PM ET
Size
22.1 KB
Accession
0001123292-19-000749
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
CANAAN X L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+743,110→ 1,188,976 total - Conversion
Series A-2 Preferred Stock
2019-05-13−5,970,000→ 0 total→ Common Stock (743,110 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−2,296,605→ 0 total→ Common Stock (285,867 underlying) - Conversion
Common Stock
2019-05-13+729,599→ 1,918,575 total - Purchase
Common Stock
2019-05-13$15.00/sh+50,000$750,000→ 2,254,442 total - Conversion
Series A-3 Preferred Stock
2019-05-13−5,861,455→ 0 total→ Common Stock (729,599 underlying) - Conversion
Common Stock
2019-05-13+445,866→ 445,866 total - Conversion
Series A-1 Preferred Stock
2019-05-13−3,582,000→ 0 total→ Common Stock (445,866 underlying) - Conversion
Common Stock
2019-05-13+285,867→ 2,204,442 total
Canaan Partners X LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+445,866→ 445,866 total - Conversion
Common Stock
2019-05-13+743,110→ 1,188,976 total - Conversion
Common Stock
2019-05-13+729,599→ 1,918,575 total - Purchase
Common Stock
2019-05-13$15.00/sh+50,000$750,000→ 2,254,442 total - Conversion
Series A-3 Preferred Stock
2019-05-13−5,861,455→ 0 total→ Common Stock (729,599 underlying) - Conversion
Series A-1 Preferred Stock
2019-05-13−3,582,000→ 0 total→ Common Stock (445,866 underlying) - Conversion
Series B-1 Preferred Stock
2019-05-13−2,296,605→ 0 total→ Common Stock (285,867 underlying) - Conversion
Common Stock
2019-05-13+285,867→ 2,204,442 total - Conversion
Series A-2 Preferred Stock
2019-05-13−5,970,000→ 0 total→ Common Stock (743,110 underlying)
Footnotes (2)
- [F1]The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
Documents
Issuer
NextCure, Inc.
CIK 0001661059
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001619859
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 7:32 PM ET
- Size
- 22.1 KB